EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Safety of Dupilumab and Risk of Cutaneous T‐Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data‐Driven Guide to Counseling Patients and Families

Maria Gnarra Buethe iD, Tyler Sy, Lawrence F Eichenfield

Pediatric Dermatology · 2026

DOI: 10.1111/pde.70285 ↗

At a glance

Übersichtsarbeit in Pediatric Dermatology, 2026. Written by Maria Gnarra Buethe and 2 co-authors. Institution: Division of Dermatology, Rady Children's Hospital-Orange County, Orange, California, USA. Major MEDLINE topics: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous. Cited 1 times so far (Crossref); 24 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Recent publications reporting increased cutaneous T‐cell lymphoma (CTCL) risk with dupilumab in atopic dermatitis (AD) have sparked debate, amplified by media coverage linking dupilumab to lymphoma. These concerns have reached pediatric populations, where we observe increasing parental hesitancy about initiating dupilumab for their children. This hesitancy is particularly acute given that dupilumab was only approved for infants aged 6 months and older in 2022—the first cohort now approaching 3–4 years of exposure. Parents understandably question the long‐term effects of decades of IL‐4/IL‐13 blockade initiated during critical immune development periods. The diagnostic overlap between AD and mycosis fungoides (the most common CTCL) complicates assessment. We examine evidence regarding dupilumab safety and CTCL risk specifically in pediatric patients, incorporating recently presented long‐term open‐label extension data, and provide recommendations for monitoring, distinguishing AD from CTCL, and counseling families navigating this complex topic.

Subjects

MeSH terms (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedSkin NeoplasmsLymphoma, T-Cell, CutaneousHumansChildInfantCounselingChild, Preschool

Author keywords

Sézary syndromeatopic dermatitisbiologic therapycutaneous T‐cell lymphoma (CTCL)dupilumabmycosis fungoidespediatricpharmacovigilance

Substances

Antibodies, Monoclonal, Humanizeddupilumab

Authors and institutions

  • Division of Dermatology, Rady Children's Hospital-Orange County, Orange, California, USA.
  • Department of Dermatology, University of California, Irvine, Irvine, California, USA.
  • Department of Pediatrics, University of California, Irvine, Irvine, California, USA.
  • Division of Pediatric and Adolescent Dermatology, Rady Children's Hospital-San Diego, San Diego, California, USA.
  • Department of Dermatology, University of California, San Diego, School of Medicine, La Jolla, California, USA.
  • Department of Pediatrics, University of California, San Diego, School of Medicine, La Jolla, California, USA.

ORCID profiles: Maria Gnarra Buethe

Cite

APA

Buethe, M. G., Sy, T., & Eichenfield, L. F. (2026). Safety of Dupilumab and Risk of Cutaneous T‐Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data‐Driven Guide to Counseling Patients and Families. Pediatric Dermatology. https://doi.org/10.1111/pde.70285

Vancouver

Buethe MG, Sy T, Eichenfield LF. Safety of Dupilumab and Risk of Cutaneous T‐Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data‐Driven Guide to Counseling Patients and Families. Pediatric Dermatology. 2026. doi:10.1111/pde.70285

BibTeX
@article{Buethe2026,
  author = {Buethe, Maria Gnarra and Sy, Tyler and Eichenfield, Lawrence F},
  title = {Safety of Dupilumab and Risk of Cutaneous T‐Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data‐Driven Guide to Counseling Patients and Families},
  journal = {Pediatric Dermatology},
  year = {2026},
  doi = {10.1111/pde.70285}
}
Start for free →